The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
N-acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of psychiatric disorders. Primarily through its antioxidant, anti-inflammatory, and glutamate modulation activity, NAC has been investigated in the treatment of neurodevelopmental disorders, schizophrenia spectrum disorders, bipolar-related disorders, depressive disorders, anxiety disorders, obsessive compulsive-related disorders, substance-use disorders, neurocognitive disorders, and chronic pain. Whilst there is ample preclinical evidence and theoretical justification for the use of NAC in the treatment of multiple psychiatric disorders, clinical trials in most disorders have yielded mixed results. However, most studies have been underpowered and perhaps too brief, with some evidence of benefit only after months of treatment with NAC. Currently NAC has the most evidence of having a beneficial effect as an adjuvant agent in the negative symptoms of schizophrenia, severe autism, depression, and obsessive compulsive and related disorders. Future research with well-powered studies that are of sufficient length will be critical to better understand the utility of NAC in the treatment of psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, the early intervention and the clinical staging models have encouraged investigations into more benign pharmacological treatments including “neutraceuticals”, that is, food or food products with health and medical benefits, such as fish oil [109], N-acetylcysteine [110], and cannabidiol [111], that may be suitable for targeting emerging psychopathology.”
From Towards a youth mental health paradigm: a perspective and roadmap (2023) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Yang (2021) · doi:10.1038/s41598-020-79139-8 · Cited by 5,035
The glutamate homeostasis hypothesis of addiction
Kalivas, P. W. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2515 · Cited by 1,350 · cited 1×
“10 Substance‐Use Disorders Chronic substance use results in changes to frontostriatal glutamatergic circuitry, resulting in compulsive alcohol/ drug seeking and loss of adaptive behavior in the presence of substance-associated environmental or interoceptive stimuli [133].”
BackgroundSelf-citationThe chemistry and biological activities of N-acetylcysteine
Samuni, Y., Goldstein, S., Dean, O. M., & Berk, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.016 · Cited by 876
Self-citationN-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why
Aldini, G., Altomare, A., Baron, G., Vistoli, G., Carini, M., Borsani, L., & Sergio, F. (2018) · Free Radical Research · doi:10.1080/10715762.2018.1468564 · Cited by 830
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse
Baker, D. A., McFarland, K., Lake, R. W., Shen, H., Tang, X.-C., Toda, S., & Kalivas, P. W. (2003) · Nature Neuroscience · doi:10.1038/nn1069 · Cited by 739
Self-citationBerk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Self-citationBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494
Self-citationNutritional psychiatry: The present state of the evidence
Marx, W., Moseley, G., Berk, M., & Jacka, F. (2017) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117002026 · Cited by 469 · cited 1×
“The anti-inflammatory activity of NAC is protective against chronic inflammation, which is implicated in the pathogenesis of many psychiatric disorders [17].”
BackgroundSelf-citationClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationGrant, J. E., Odlaug, B. L., & Won Kim, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.60 · Cited by 424
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Self-citationWWARN K13 Genotype-Phenotype Study Group (2019) · BMC Medicine · doi:10.1186/s12916-018-1207-3 · Cited by 320
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306
Grant, J. E., Kim, S. W., & Odlaug, B. L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.021 · Cited by 301
Karuppagounder, S. S., Alin, L., Chen, Y., Brand, D., Bourassa, M. W., Dietrich, K., Wilkinson, C. M., Nadeau, C. A., Kumar, A., Perry, S., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25356 · Cited by 298
A randomized controlled pilot trial of oral N-acetylcysteine in children with autism
Hardan, A. Y., Fung, L. K., Libove, R. A., Obukhanych, T. V., Nair, S., Herzenberg, L. A., Frazier, T. W., & Tirouvanziam, R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.014 · Cited by 293
Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases
Tardiolo, G., Bramanti, P., & Mazzon, E. (2018) · Molecules · doi:10.3390/molecules23123305 · Cited by 285
Prediction of Psychosis by Mismatch Negativity
Bodatsch, M., Ruhrmann, S., Wagner, M., Müller, R., Schultze-Lutter, F., Frommann, I., Brinkmeyer, J., Gaebel, W., Maier, W., Klosterkötter, J., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.057 · Cited by 283
Raghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
Self-citationThe Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and Humans
Knackstedt, L. A., LaRowe, S., Mardikian, P., Malcolm, R., Upadhyaya, H., Hedden, S., Markou, A., & Kalivas, P. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.040 · Cited by 260
Self-citationControlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease
Adair, J. C., Knoefel, J. E., & Morgan, N. (2001) · Neurology · doi:10.1212/wnl.57.8.1515 · Cited by 240
Zhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225
Self-citationMichel, T. M., Frangou, S., Thiemeyer, D., Camara, S., Jecel, J., Nara, K., Brunklaus, A., Zoechling, R., & Riederer, P. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.04.013 · Cited by 218
Is Cocaine Desire Reduced by N -Acetylcysteine?
LaRowe, S. D., Myrick, H., Hedden, S., Mardikian, P., Saladin, M., McRae, A., Brady, K., Kalivas, P. W., & Malcolm, R. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1115 · Cited by 210
Self-citationHoffer, M. E., Balaban, C., Slade, M. D., Tsao, J. W., & Hoffer, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054163 · Cited by 207 · cited 2×
“An RCT of 81 actively serving US military members in Iraq explored this topic [191].”
BackgroundMethodJuvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
Cabungcal, J.-H., Counotte, D. S., Lewis, E. M., Tejeda, H. A., Piantadosi, P., Pollock, C., Calhoon, G. G., Sullivan, E. M., Presgraves, E., Kil, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.028 · Cited by 204 · cited 2×
“Treatment of these rats with NAC during adolescence and prior to the onset of symptoms prevented the reduction of prefrontal parvalbumin immunoreactive interneuron activity [57].”
BackgroundThe Addictive Model of Self-Harming (Non-suicidal and Suicidal) Behavior
Blasco-Fontecilla, H., Fernández-Fernández, R., Colino, L., Fajardo, L., Perteguer-Barrio, R., & de Leon, J. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00008 · Cited by 203
Lafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 199
N‐Acetylcysteine suppresses TNF‐induced NF‐κB activation through inhibition of IκB kinases
Oka, S.-I., Kamata, H., Kamata, K., Yagisawa, H., & Hirata, H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01464-2 · Cited by 186
Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181 · cited 10×
“Psychotherapy also has limited evidence in treating the depressive symptoms of bipolar affective disorder (BPAD) [3].”
BackgroundMethodSelf-citationSafety and Tolerability of N‐Acetylcysteine in Cocaine‐Dependent Individuals
LaRowe, S. D., Mardikian, P., Malcolm, R., Myrick, H., Kalivas, P., McFarland, K., Saladin, M., McRae, A., & Brady, K. (2006) · The American Journal on Addictions · doi:10.1080/10550490500419169 · Cited by 180
Self-citationAnticevic, A., Hu, X., Xiao, Y., Hu, J., Li, F., Bi, F., Cole, M. W., Savic, A., Yang, G. J., Repovs, G., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2310-14.2015 · Cited by 178
Berk, M., Dean, O. M., Cotton, S. M., Jeavons, S., Tanious, M., Kohlmann, K., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08454 · Cited by 172 · cited 5×
“They also found significant improvement in the functioning measures of Longitudinal Interval Follow-up Evaluation-Range of Impaired Functioning Tool (LIFE-RIFT) and Streamlined Longitudinal Interview Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation (SLICE-LIFE) [79].”
BackgroundMethodSelf-citationN-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial
Grant, J. E., Chamberlain, S. R., Redden, S. A., Leppink, E. W., Odlaug, B. L., & Kim, S. W. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0060 · Cited by 172
Bloch, M. H., Panza, K. E., Grant, J. E., Pittenger, C., & Leckman, J. F. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.12.020 · Cited by 171
A double‐blind placebo‐controlled trial of N‐acetylcysteine in the treatment of cocaine dependence
LaRowe, S. D., Kalivas, P. W., Nicholas, J. S., Randall, P. K., Mardikian, P. N., & Malcolm, R. J. (2013) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12034.x · Cited by 164
Self-citationConus, P., Seidman, L. J., Fournier, M., Xin, L., Cleusix, M., Baumann, P. S., Ferrari, C., Cousins, A., Alameda, L., Gholam-Rezaee, M., et al. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx093 · Cited by 162
Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia
Brockhaus‐Dumke, A., Tendolkar, I., Pukrop, R., Schultze‐Lutter, F., Klosterkötter, J., & Ruhrmann, S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.016 · Cited by 158
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.020 · Cited by 157 · cited 1×
“These findings were not replicated in a large (302 participants) 12-week RCT that failed to show that NAC (2,400 mg/day) combined with contingency management was superior to placebo and contingency management in achieving abstinence from cannabis in adults [152].”
BackgroundFarokhnia, M., Azarkolah, A., Adinehfar, F., Khodaie-Ardakani, M.-R., Hosseini, S.-M.-R., Yekehtaz, H., Tabrizi, M., Rezaei, F., Salehi, B., Sadeghi, S.-M.-H., et al. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000001 · Cited by 155
Ghanizadeh, A., & Moghimi-Sarani, E. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-196 · Cited by 152
Schmaal, L., Veltman, D. J., Nederveen, A., van den Brink, W., & Goudriaan, A. E. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.66 · Cited by 148
Amen, S. L., Piacentine, L. B., Ahmad, M. E., Li, S.-J., Mantsch, J. R., Risinger, R. C., & Baker, D. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.226 · Cited by 140
Afshar, H., Roohafza, H., Mohammad-Beigi, H., Haghighi, M., Jahangard, L., Shokouh, P., Sadeghi, M., & Hafezian, H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272677d · Cited by 138
Lehmann, M. L., Weigel, T. K., Poffenberger, C. N., & Herkenham, M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0184-19.2019 · Cited by 138 · cited 2×
“In that model, NAC reduced both oxidative stress and anxiety behaviors [85].”
BackgroundRemington, R., Bechtel, C., Larsen, D., Samar, A., Doshanjh, L., Fishman, P., Luo, Y., Smyers, K., Page, R., Morrell, C., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142499 · Cited by 134
Farhat, L. C., Olfson, E., Nasir, M., Levine, J. L. S., Li, F., Miguel, E. C., & Bloch, M. H. (2020) · Depression and Anxiety · doi:10.1002/da.23028 · Cited by 133 · cited 3×
“A meta-analysis of these two RCTs published in 2020 concluded that NAC was significantly superior to placebo in treating trichotillomania seen on MGH-HPS [121].”
MethodRemington, R., Chan, A., Paskavitz, J., & Shea, T. B. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508325094 · Cited by 128
Chan, A., Paskavitz, J., Remington, R., Rasmussen, S., & Shea, T. B. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508325093 · Cited by 127
Jones, S. V., & Kounatidis, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01805 · Cited by 127
Reichel, C. M., Moussawi, K., Do, P. H., Kalivas, P. W., & See, R. E. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179317 · Cited by 124
Self-citationWink, L. K., Adams, R., Wang, Z., Klaunig, J. E., Plawecki, M. H., Posey, D. J., McDougle, C. J., & Erickson, C. A. (2016) · Molecular Autism · doi:10.1186/s13229-016-0088-6 · Cited by 117
Sun, W., & Rebec, G. V. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1413-06.2006 · Cited by 115
N-acetylcysteine for major depressive episodes in bipolar disorder
Magalhães, P. V., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2011) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462011000400011 · Cited by 114
Self-citationNikoo, M., Radnia, H., Farokhnia, M., Mohammadi, M.-R., & Akhondzadeh, S. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000063 · Cited by 112
The effect of N-acetylcysteine (NAC) on human cognition – A systematic review
Skvarc, D. R., Dean, O. M., Byrne, L. K., Gray, L., Lane, S., Lewis, M., Fernandes, B. S., Berk, M., & Marriott, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.013 · Cited by 111
Self-citationN‐Acetylcysteine (NAC) in Young Marijuana Users: An Open‐Label Pilot Study
Gray, K. M., Watson, N. L., Carpenter, M. J., & LaRowe, S. D. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00027.x · Cited by 109
Paydary, K., Akamaloo, A., Ahmadipour, A., Pishgar, F., Emamzadehfard, S., & Akhondzadeh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12370 · Cited by 107
Yolland, C. O., Hanratty, D., Neill, E., Rossell, S. L., Berk, M., Dean, O. M., Castle, D. J., Tan, E. J., Phillipou, A., Harris, A. W., et al. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419893439 · Cited by 107
Self-citationN-acetyl cysteine in the treatment of grooming disorders.
Odlaug, B., & Grant, J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000264976.86990.00 · Cited by 104
Magalhães, P. V., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.001 · Cited by 101
Self-citationSepehrmanesh, Z., Heidary, M., Akasheh, N., Akbari, H., & Heidary, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.001 · Cited by 101
Berk, M., Turner, A., Malhi, G. S., Ng, C. H., Cotton, S. M., Dodd, S., Samuni, Y., Tanious, M., McAulay, C., Dowling, N., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1257-1 · Cited by 100
Self-citationN-acetylcysteine prevents stress-induced anxiety behavior in zebrafish
Mocelin, R., Herrmann, A. P., Marcon, M., Rambo, C. L., Rohden, A., Bevilaqua, F., de Abreu, M. S., Zanatta, L. C. B., Elisabetsky, E., Barcellos, L. J. G., et al. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.08.006 · Cited by 100
Breier, A., Liffick, E., Hummer, T. A., Vohs, J. L., Yang, Z., Mehdiyoun, N. F., Visco, A. C., Metzler, E., Zhang, Y., & Francis, M. M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.012 · Cited by 98
Oliver, G., Dean, O., Camfield, D., Blair-West, S., Ng, C., Berk, M., & Sarris, J. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.12 · Cited by 96 · cited 12×
“There have been six RCTs investigating NAC treating OCD, four with NAC as adjuvant therapy to selective serotonin reuptake inhibitors (SSRIs) and two as single therapy, with doses ranging from 2000 to 3000 mg/day [102–107].”
BackgroundSelf-citationBerk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-91 · Cited by 96
Self-citationGrant, J. E., Odlaug, B. L., & Kim, S. W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.018 · Cited by 94
Schmaal, L., Berk, L., Hulstijn, K. P., Cousijn, J., Wiers, R. W., & van den Brink, W. (2011) · European Addiction Research · doi:10.1159/000327682 · Cited by 93
Costa, D. L. C., Diniz, J. B., Requena, G., Joaquim, M. A., Pittenger, C., Bloch, M. H., Miguel, E. C., & Shavitt, R. G. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11101 · Cited by 93
Smaga, I., Pomierny, B., Krzyżanowska, W., Pomierny-Chamioło, L., Miszkiel, J., Niedzielska, E., Ogorka, A. Z. T., & Filip, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.018 · Cited by 91
Back, S. E., McCauley, J. L., Korte, K. J., Gros, D. F., Leavitt, V., Gray, K. M., Hamner, M. B., DeSantis, S. M., Malcolm, R., Brady, K. T., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10239 · Cited by 91
Self-citationFroeliger, B., McConnell, P. A., Stankeviciute, N., McClure, E. A., Kalivas, P. W., & Gray, K. M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.021 · Cited by 90
Self-citationSpencer, S., Neuhofer, D., Chioma, V. C., Garcia-Keller, C., Schwartz, D. J., Allen, N., Scofield, M. D., Ortiz-Ithier, T., & Kalivas, P. W. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.04.016 · Cited by 82
Self-citationCarmeli, C., Knyazeva, M. G., Cuénod, M., & Do, K. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029341 · Cited by 81
Siemsen, B. M., Reichel, C. M., Leong, K. C., Garcia-Keller, C., Gipson, C. D., Spencer, S., McFaddin, J. A., Hooker, K. N., Kalivas, P. W., & Scofield, M. D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.040 · Cited by 81
Self-citationSarris, J., Oliver, G., Camfield, D., Dean, O., Dowling, N., Smith, D. J., Murphy, J., Menon, R., Berk, M., Blair-West, S., et al. (2015) · CNS Drugs · doi:10.1007/s40263-015-0272-9 · Cited by 79
Self-citationDean, O. M., Gray, K. M., Villagonzalo, K.-A., Dodd, S., Mohebbi, M., Vick, T., Tonge, B. J., & Berk, M. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416652735 · Cited by 76
Self-citationLee, T.-M., Lee, K.-M., Lee, C.-Y., Lee, H.-C., Tam, K.-W., & Loh, E.-W. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420952540 · Cited by 75
N‐acetylcysteine as a new prominent approach for treating psychiatric disorders
Smaga, I., Frankowska, M., & Filip, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15456 · Cited by 72
An open‐label pilot study of N‐acetylcysteine for skin‐picking in Prader–Willi syndrome
Miller, J. L., & Angulo, M. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36306 · Cited by 71
Hashimoto, K., Tsukada, H., Nishiyama, S., Fukumoto, D., Kakiuchi, T., Shimizu, E., & Iyo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300512 · Cited by 70
Mocelin, R., Marcon, M., D’ambros, S., de Mattos, J. N., Sachett, A., Siebel, A. M., Herrmann, A. P., & Piato, Â. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1165-y · Cited by 70
N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study
Prado, E., Maes, M., Piccoli, L. G., Baracat, M., Barbosa, D. S., Franco, O., Dodd, S., Berk, M., & Vargas Nunes, S. O. (2015) · Redox Report · doi:10.1179/1351000215y.0000000004 · Cited by 69
Self-citationEffect of N‐acetylcysteine on motivation, seeking and relapse to ethanol self‐administration
Lebourgeois, S., González‐Marín, M. C., Jeanblanc, J., Naassila, M., & Vilpoux, C. (2018) · Addiction Biology · doi:10.1111/adb.12521 · Cited by 69
Hodebourg, R., Murray, J. E., Fouyssac, M., Puaud, M., Everitt, B. J., & Belin, D. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.13894 · Cited by 68
N-acetylcysteine in the Treatment of Trichotillomania
Rodrigues-Barata, A. R., Tosti, A., Rodríguez-Pichardo, A., & Camacho-Martínez, F. (2012) · International Journal of Trichology · doi:10.4103/0974-7753.100090 · Cited by 67
Mousavi, S. G., Sharbafchi, M. R., Salehi, M., Peykanpour, M., Sichani, N. K., & Maracy, M. R. (2015) · PubMed · Cited by 67
Antidepressant-like effects of N-acetyl-L-cysteine in rats
Ferreira, F. R., Biojone, C., Joca, S. R. L., & Guimarães, F. S. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283123c98 · Cited by 63
Ghanizadeh, A., Derakhshan, N., & Berk, M. (2013) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011312030003 · Cited by 63
Self-citationN-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li, F., Welling, M. C., Johnson, J. A., Coughlin, C., Mulqueen, J., Jakubovski, E., Coury, S., Landeros-Weisenberger, A., & Bloch, M. H. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0041 · Cited by 61
Effects of N‐acetyl cysteine on cognitive function in bipolar disorder
Dean, O. M., Bush, A. I., Copolov, D. L., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson‐Hunt, M., & Berk, M. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02392.x · Cited by 58 · cited 2×
“Likewise, NAC was found to have no significant effect on cognition in patients with bipolar disorder compared to placebo [67].”
BackgroundMethodSelf-citationNail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting
Berk, M., Jeavons, S., Dean, O. M., Dodd, S., Moss, K., Gama, C. S., & Malhi, G. S. (2009) · CNS Spectrums · doi:10.1017/s1092852900023002 · Cited by 58
Self-citationA preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania
Vieira da Silva Magalhães, P., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413481631 · Cited by 58
Self-citationThe effect of N-acetylcysteine on alcohol use during a cannabis cessation trial
Squeglia, L. M., Tomko, R. L., Baker, N. L., McClure, E. A., Book, G. A., & Gray, K. M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.12.005 · Cited by 57
N-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats
Schneider, R., Santos, C. F., Clarimundo, V. S., Dalmaz, C., Elisabetsky, E., & Gomez, R. (2015) · Alcohol · doi:10.1016/j.alcohol.2015.01.009 · Cited by 57
Hauer, K., Hildebrandt, W., Sehl, Y., Edler, L., Oster, P., & Dröge, W. (2003) · Journal of molecular medicine · doi:10.1007/s00109-002-0406-7 · Cited by 56
Klauser, P., Xin, L., Fournier, M., Griffa, A., Cleusix, M., Jenni, R., Cuenod, M., Gruetter, R., Hagmann, P., Conus, P., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0266-8 · Cited by 56
Bernabucci, M., Notartomaso, S., Zappulla, C., Fazio, F., Cannella, M., Motolese, M., Battaglia, G., Bruno, V., Gradini, R., & Nicoletti, F. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-77 · Cited by 54
Rossell, S. L., Francis, P. S., Galletly, C. A., Harris, A. W. F., Siskind, D. J., Berk, M., Bozaoglu, K., Dark, F. L., Dean, O. M., Liu, D., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1030-3 · Cited by 54
Self-citationGlutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction
Heinsbroek, J. A., Vries, T. J. D., & Peters, J. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039602 · Cited by 54
Bauer, I. E., Green, C., Colpo, G. D., Teixeira, A. L., Selvaraj, S., Durkin, K., Zunta-Soares, G. B., & Soares, J. C. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12200 · Cited by 53
Valvassori, S. S., Petronilho, F. C., Réus, G. Z., Steckert, A. V., Oliveira, V. B. M., Boeck, C. R., Kapczinski, F. P., Dal‐Pizzol, F., & Quevedo, J. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.02.012 · Cited by 52
Ghanizadeh, A. J., Mohammadi, M. R., Bahraini, S., Keshavarzi, Z., Firoozabadi, A., & Shoushtari, A. A. (2017) · PubMed Central · Cited by 51
Sözbir, E., & Nazıroğlu, M. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9769-7 · Cited by 50
Ellegaard, P. K., Licht, R. W., Nielsen, R. E., Dean, O. M., Berk, M., Poulsen, H. E., Mohebbi, M., & Nielsen, C. T. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.083 · Cited by 50
Self-citationAnxiolytic properties of N -acetylcysteine in mice
Santos, P. C. D., Herrmann, A. P., Benvenutti, R., Noetzold, G., Giongo, F. K., Gama, C. S., Piato, Â., & Elisabetsky, E. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.010 · Cited by 49
Porcu, M., Urbano, M. R., Verri, W. A., Jr., Barbosa, D. S., Baracat, M. M., Vargas, H. O., Machado, R. C. B. R., Pescim, R. R., & Nunes, S. O. V. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.02.056 · Cited by 49
Inflammation in Mental Disorders: Is the Microbiota the Missing Link?
Marin, S., Hé, Y., Butler, K., & Tsuang, M. T. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00535-1 · Cited by 49
N-acetylcysteine for treatment of autism, a case report.
Ghanizadeh, A. J., & Derakhshan, N. (2012) · PubMed Central · Cited by 46
Chen, Y.-W., Lin, H., Ng, M.-C., Hsiao, Y., Wang, C.-C., Gean, P., & Chen, P. S. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00219 · Cited by 46
Rapado‐Castro, M., Berk, M., Venugopal, K., Bush, A. I., Dodd, S., & Dean, O. M. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.10.002 · Cited by 44
Self-citationModulation of [3H]Dopamine Release by Glutathione in Mouse Striatal Slices
Janáky, R., Dohovics, R., Saransaari, P., & Oja, S. S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9315-z · Cited by 43
Kishi, T., Miyake, N., Okuya, M., Sakuma, K., & Iwata, N. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05629-2 · Cited by 43
Raza, H., John, A., & Shafarin, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103379 · Cited by 43
Woodcock, E. A., Lundahl, L. H., Khatib, D., Stanley, J. A., & Greenwald, M. K. (2020) · Addiction Biology · doi:10.1111/adb.12900 · Cited by 42
Retsa, C., Knebel, J., Geiser, E., Ferrari, C., Jenni, R., Fournier, M., Alameda, L., Baumann, P., Clarke, S., Conus, P., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.008 · Cited by 40
N -Acetylcysteine for Nonsuicidal Self-Injurious Behavior in Adolescents: An Open-Label Pilot Study
Cullen, K. R., Klimes-Dougan, B., Westlund Schreiner, M., Carstedt, P., Marka, N., Nelson, K., Miller, M. J., Reigstad, K., Westervelt, A., Gunlicks-Stoessel, M., et al. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0032 · Cited by 40
Garcia‐Keller, C., Smiley, C., Monforton, C., Melton, S., Kalivas, P. W., & Gass, J. (2020) · Addiction Biology · doi:10.1111/adb.12798 · Cited by 40
Self-citationCorticostriatal circuitry in regulating diseases characterized by intrusive thinking
Kalivas, B. C., & Kalivas, P. W. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/pkalivas · Cited by 39
Self-citationAn open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers
McClure, E. A., Baker, N. L., Gipson, C. D., Carpenter, M. J., Roper, A. P., Froeliger, B. E., Kalivas, P. W., & Gray, K. M. (2015) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2014.933839 · Cited by 38
Self-citationBloch, M. H., Panza, K. E., Yaffa, A., de Alvarenga, P. G., Jakubovski, E., Mulqueen, J. M., Landeros‐Weisenberger, A., & Leckman, J. F. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0109 · Cited by 38
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation
Squeglia, L. M., Baker, N. L., McClure, E. A., Tomko, R. L., Adisetiyo, V., & Gray, K. M. (2016) · Addictive Behaviors · doi:10.1016/j.addbeh.2016.08.001 · Cited by 38
Kitamura, Y., Ushio, S., Sumiyoshi, Y., Wada, Y., Miyazaki, I., Asanuma, M., & Sendo, T. (2021) · Pharmacology · doi:10.1159/000512117 · Cited by 38
Santos, P. C. D., Herrmann, A. P., Elisabetsky, E., & Piato, Â. (2018) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0005 · Cited by 37
Visacri, M. B., Quintanilha, J. C. F., de Sousa, V. M., Amaral, L. S., Ambrósio, R. D. F. L., Calonga, L., Curi, S. F. B. B., Leme, M. F. D. T., Chone, C. T., Altemani, J. M. C., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2072 · Cited by 37
Mullier, E., Roine, T., Griffa, A., Xin, L., Baumann, P. S., Klauser, P., Cleusix, M., Jenni, R., Alemàn-Gómez, Y., Gruetter, R., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz022 · Cited by 37
N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial
McKetin, R., Dean, O. M., Turner, A., Kelly, P. J., Quinn, B., Lubman, D. I., Dietze, P., Carter, G. L., Higgs, P., Sinclair, B., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101005 · Cited by 36
Self-citationSchulte, M. H. J., Wiers, R. W. H. J., Boendermaker, W. J., Goudriaan, A. E., van den Brink, W., van Deursen, D. S., Friese, M., Brede, E., & Waters, A. J. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.11.044 · Cited by 35
Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia
McQueen, G., Lally, J., Collier, T., Zelaya, F., Lythgoe, D. J., Barker, G. J., Stone, J. M., McGuire, P., MacCabe, J. H., & Egerton, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4997-2 · Cited by 35
N-Acetylcysteine Protects against the Anxiogenic Response to Cisplatin in Rats
Vukovic, R., Kumburović, I., Joksimović, J., Jovicic, N. U., Stanković, J. S. K., Mihailović, V. B., Djuric, M., Veličković, S., Arnaut, A., Selaković, D., et al. (2019) · Biomolecules · doi:10.3390/biom9120892 · Cited by 35
Yang, C., Bosker, F. J., Li, J., & Schoevers, R. A. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1845-1 · Cited by 34
Durieux, A. M. S., Fernandes, C., Murphy, D., Labouesse, M. A., Giovanoli, S., Meyer, U., Li, Q., So, P., & McAlonan, G. M. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00343 · Cited by 34
N-acetylcysteine decreased nicotine reward-like properties and withdrawal in mice
Bowers, M. S., Jackson, A. B., Maldoon, P. P., & Damaj, M. I. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4179-4 · Cited by 33
A potential role for N‐acetylcysteine in the management of methamphetamine dependence
McKetin, R., Dean, O. M., Baker, A., Carter, G. L., Turner, A., Kelly, P. J., & Berk, M. (2016) · Drug and Alcohol Review · doi:10.1111/dar.12414 · Cited by 33
Self-citationN‐acetylcysteine yields sex‐specific efficacy for cue‐induced reinstatement of nicotine seeking
Goenaga, J. G., Powell, G. L., Leyrer‐Jackson, J. M., Piña, J., Phan, S., Prakapenka, A. V., Koebele, S. V., Namba, M. D., McClure, E. A., Bimonte‐Nelson, H. A., et al. (2019) · Addiction Biology · doi:10.1111/adb.12711 · Cited by 33
N-Acetyl-L-Cysteine Inhibits Marble-Burying Behavior in Mice
Egashira, N., Shirakawa, A., Abe, M., Niki, T., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11228sc · Cited by 32
N-acetylcysteine in the treatment of skin-picking disorder
Silva-Netto, R., Jesus, G., Nogueira, M., & Tavares, H. (2014) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1154 · Cited by 32
Tomko, R. L., Baker, N. L., Hood, C. O., Gilmore, A. K., McClure, E. A., Squeglia, L. M., McRae‐Clark, A. L., Sonne, S. C., & Gray, K. M. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05384-z · Cited by 30
Morais‐Silva, G., Alves, G. C., & Marin, M. T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.009 · Cited by 29
Nery, F. G., Li, W., DelBello, M. P., & Welge, J. A. (2021) · Bipolar Disorders · doi:10.1111/bdi.13039 · Cited by 29 · cited 9×
“It investigated the effects of adjunctive NAC (2000 mg/day) over 28 weeks (24 weeks of intervention and an additional 4 weeks of followup) in 74 patients with bipolar disorder (I and II) and found that the NAC group showed significant improvement in the Montgomery Åsberg Depression Rating Scale (MADRS) and Bipolar Dep…”
BackgroundInfluentialSystemic illness moderates the impact of N-acetyl cysteine in bipolar disorder
Magalhães, P. V., Dean, O. M., Bush, A. I., Copolov, D. L., Weisinger, D., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.011 · Cited by 28
Self-citationDas, P., Tanious, M., Fritz, K., Dodd, S., Dean, O. M., Berk, M., & Malhi, G. S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412474074 · Cited by 28
Self-citationMohiuddin, M., Pivetta, B., Gilron, I., & Khan, J. S. (2021) · Pain Medicine · doi:10.1093/pm/pnab042 · Cited by 28
Trichotillomania: a good response to treatment with N-acetylcysteine
Barroso, L. A. L., Sternberg, F., Souza, M. N. I. D. F. E., & Nunes, G. J. D. B. (2017) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20175435 · Cited by 28
Schulte, M. H. J., Goudriaan, A. E., Kaag, A. M., Kooi, D., van den Brink, W., Wiers, R. W. H. J., & Schmaal, L. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117730660 · Cited by 28
Charntikov, S., Pittenger, S. T., Pudiak, C. M., & Bevins, R. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.021 · Cited by 27
Strawn, J. R., & Saldaña, S. N. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0066 · Cited by 26 · cited 1×
“There has been one published case report of NAC (at 2,400 mg/day) as an augmentation to sertraline in treating a 17-year-old male with generalized anxiety disorder and social phobia resulting in a reduction in his CGI-S from 5 to 2 over an 8-week period [92].”
BackgroundGere‐Pászti, E., & Jakus, J. (2009) · Biomedical Chromatography · doi:10.1002/bmc.1171 · Cited by 26
Bentzley, J. P., Tomko, R. L., & Gray, K. M. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.12.003 · Cited by 26
Back, S. E., Gray, K. M., Ana, E. J. S., Jones, J. L., Jarnecke, A. M., Joseph, J. E., Prisciandaro, J. J., Killeen, T. K., Brown, D. G., Taimina, L., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.105961 · Cited by 26
Self-citationN-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series
Ameringen, M. V., Patterson, B. A., Simpson, W. S., & Turna, J. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2012.10.003 · Cited by 26
N -Acetylcysteine as Treatment for Self-Injurious Behavior in a Child with Autism
Marler, S., Sanders, K. B., & Veenstra-VanderWeele, J. M. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0137 · Cited by 24
N‐Acetylcysteine in the treatment of trichotillomania: remarkable results in two patients
Özcan, D., & Seçkin, D. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13690 · Cited by 24
N ‐acetylcysteine in trichotillomania: a panacea for compulsive skin disorders?
Taylor, M., & Bhagwandas, K. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13080 · Cited by 23
Schulte, M. H. J., Wiers, R. W. H. J., Boendermaker, W. J., Goudriaan, A. E., van den Brink, W., van Deursen, D. S., Friese, M., Brede, E., & Waters, A. J. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.03.023 · Cited by 23
Perçinel, İ., & Yazıcı, K. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000210 · Cited by 23
Panizzutti, B., Bortolasci, C. C., Hasebe, K., Kidnapillai, S., Gray, L. J., Walder, K. R., Berk, M., Mohebbi, M., Dodd, S., Gama, C. S., et al. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.13 · Cited by 22
Self-citationTrichoteiromania: Good Response to Treatment with N-Acetylcysteine
Salas-Callo, C. I., & Pirmez, R. (2019) · Skin Appendage Disorders · doi:10.1159/000497167 · Cited by 22
Mitchell, E. J., Thomson, D. M., Openshaw, R. L., Bristow, G. C., Dawson, N., Pratt, J. A., & Morris, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-69130-8 · Cited by 22
Tomko, R. L., Gilmore, A. K., & Gray, K. M. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.05.014 · Cited by 21
Schulte, M. H. J., Kaag, A. M., Boendermaker, W. J., van den Brink, W., Goudriaan, A. E., & Wiers, R. W. H. J. (2019) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2019.03.011 · Cited by 20
Yazıcı, K., & Perçinel, I. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000362 · Cited by 20
Repetitive Behaviors Treated With N-Acetylcysteine: Case Series
Kılıç, F., & Keleş, S. (2019) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000352 · Cited by 20
Chang, C.-T., Hsieh, P.-J., Lee, H., Lo, C.-H., Tam, K., & Loh, E. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.282 · Cited by 20
Amen, D., Taylor, D. V., Ojala, K., Kaur, J., & Willeumier, K. (2013) · PubMed · Cited by 19
Schmidt, S. J., Hurlemann, R., Schultz, J., Wasserthal, S., Kloss, C., Maier, W., Meyer‐Lindenberg, A., Hellmich, M., Muthesius, A., Pantel, T., et al. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12781 · Cited by 19
Bernardo, M., Dodd, S., Gama, C. S., Copolov, D. L., Dean, O., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Bush, A. I., et al. (2009) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2009.00397.x · Cited by 17
Self-citationMaier, A., Dharan, A. L., Oliver, G., Berk, M., Redston, S., Back, S. E., Kalivas, P. W., Ng, C. H., & Kanaan, R. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02793-9 · Cited by 17
Self-citationEffect of N-acetylcysteine on clozapine-induced sialorrhea in schizophrenic patients: a case series
Uzun, Ö., Bolu, A., & Çelik, C. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000297 · Cited by 16
Cotton, S., Berk, M., Watson, A., Wood, S. J., Allott, K., Bartholomeusz, C., Bortolasci, C. C., Walder, K. R., O'Donoghue, B. N., Dean, O. M., et al. (2019) · Trials · doi:10.1186/s13063-019-3786-5 · Cited by 16
Self-citationPittas, S., Theodoridis, X., Haidich, A., Bozikas, P.-V., & Papazisis, G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05789-9 · Cited by 16
Effects of N-Acetyl Cysteine on Suicidal Ideation in Bipolar Depression
Waterdrinker, A., Berk, M., Venugopal, K., Rapado‐Castro, M., Turner, A., & Dean, O. M. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14l09378 · Cited by 15
Self-citationMcQueen, G., Lay, A., Lally, J., Gabay, A. S., Collier, T., Lythgoe, D. J., Barker, G. J., Stone, J. M., McGuire, P. K., MacCabe, J. H., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05382-1 · Cited by 15
Miyake, N., Miyamoto, S., Yamashita, Y., Ninomiya, Y., Tenjin, T., & Yamaguchi, N. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000445 · Cited by 14
Gipson, C. D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.007 · Cited by 14
Arancini, L., Bortolasci, C. C., Dodd, S., Dean, O. M., & Berk, M. (2019) · Trials · doi:10.1186/s13063-019-3628-5 · Cited by 13
Self-citationPesko, M. J., Burbige, E. M., Sannar, E. M., Beresford, C. A., Rogers, C., Ariefdjohan, M. W., & Stutzman, D. L. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.2.149 · Cited by 12
A Pilot Examination of Oxidative Stress in Trichotillomania
Grant, J. E., & Chamberlain, S. R. (2018) · Psychiatry Investigation · doi:10.30773/pi.2018.09.07.1 · Cited by 11
Acetylcysteine for treatment of autism spectrum disorder symptoms
Stutzman, D. L., & Dopheide, J. A. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150072 · Cited by 11
Huang, N., Cao, B., Brietzke, E. M., Park, C., Cha, D. S., Pan, Z., Zhu, J., Liu, Y., Xie, Q., Zeng, J., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.11.064 · Cited by 11
Pyatoykina, A. S., Zhilyaeva, T. V., Semennov, I. V., Mishanov, G. A., Blagonravova, A. S., & Mazo, G. E. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202012009166 · Cited by 11
Yang, Y. S., Davis, M. C., Wynn, J. K., Hellemann, G., Green, M. F., & Marder, S. R. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.01.036 · Cited by 10
Gadallah, A.-H., Ebada, M. A., Gadallah, A., Ahmed, H., Rashad, W., Eid, K., Bahbah, E., & Alkanj, S. (2020) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2020.100529 · Cited by 10
Nery, F. G., Tallman, M. J., Cecil, K. M., Blom, T. J., Patino, L. R., Adler, C. M., & DelBello, M. P. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13149 · Cited by 10
Yazıcı, K., & Perçinel, I. (2014) · Journal of child and adolescent psychopharmacology · doi:10.1089/cap.2014.0053 · Cited by 9
Sahasrabudhe, S. A., Silamongkol, T., Park, Y. W., Colette, A. A., Eberly, L. E., Klimes‐Dougan, B., Coles, L. D., Öz, G., Mueller, B. A., Kartha, R. V., et al. (2021) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20210007 · Cited by 9
N-Acetylcysteine Blocks Serotonin 1B Agonist-Induced OCD-Related Behavior in Mice
Allen, E. M., Hughes, E. F., Anderson, C., & Woehrle, N. S. (2018) · Behavioral Neuroscience · doi:10.1037/bne0000251 · Cited by 6
N-Acetylcysteine augmentation in refractory obsessive–compulsive disorder
Bhaskara, S. (2019) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180179 · Cited by 6
N-Acetylcysteine for Neuropsychiatric Symptoms in a Woman With Williams Syndrome
Pineiro, M. L., Roberts, A. M., Waxler, J. L., Mullett, J. E., Pober, B. R., & McDougle, C. J. (2014) · Journal of Child Neurology · doi:10.1177/0883073813512025 · Cited by 5
[A girl with self-harm treated with N-acetylcysteine (NAC)].
Rus, C. P. (2018) · PubMed · Cited by 5
Schulte, M. H. J., Goudriaan, A. E., Boendermaker, W. J., van den Brink, W., & Wiers, R. W. H. J. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136146 · Cited by 5
Cohen, L. J., & Sclar, D. A. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11096tx7c · Cited by 4
N-Acetyl Cysteine and Curcumin in Pediatric Acute-Onset Neuropsychiatric Syndrome
Moore, K. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0165 · Cited by 4
Trichotillomania treated with n-acetylcysteine
Kılıç, F., & Keleş, S. (2018) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2018.1472907 · Cited by 4
Narasimha, V. L., Shukla, L., Shyam, R. S., Kandasamy, A., & Benegal, V. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_16_19 · Cited by 3
N-acetylcysteine for managing neurotic excoriation: encouraging results in two patients
Özcan, D. (2021) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2020.06.021 · Cited by 3
Potential Benefits of N-Acetylcysteine in Preventing Pregabalin-Induced Seeking-Like Behavior
Almalki, A. H., Alsaab, H. O., Alsanie, W. F., Gaber, A., Alkhalifa, T., Almalki, A., Alzahrani, O., Grégio, A. M. T., Alhadidi, Q., Shah, Z. A., et al. (2021) · Healthcare · doi:10.3390/healthcare9040376 · Cited by 3
Research works printed but not linked: 1
- Zhang J, Chen B, Lu J. Treatment effect of risperidone alone and combined with N-acetyl-cysteine for first-episode schizophrenic patients. J Clin Psychiatry. 2015;1005:394–6.
Cited by
Towards a youth mental health paradigm: a perspective and roadmap
Uhlhaas, P. J., Davey, C. G., Mehta, U. M., Shah, J., Torous, J., Allen, N. B., Avenevoli, S., Bella-Awusah, T., Chanen, A., Chen, E. Y. H., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02202-z · Cited by 318
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Lee, D. K., & Lipner, S. R. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116370 · Cited by 47
Metadata
- Authors
- Bradlow, R. C. J., Berk, M., Kalivas, P. W., Back, S. E., & Kanaan, R. A.
- Affiliations
- Eastern Health (AU)
- Barwon Health (AU)
- Medical University of South Carolina (US)
- The University of Melbourne (AU)
- Corresponding author
- Kanaan, Richard A.
- Venue
- CNS Drugs
- Published
- 2022-03-22
- Volume
- 36
- Issue
- 5
- Pages
- 451-482
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC9095537
- OpenAlex
- W4220730089
- Cited by
- 87
- References
- 200
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 26 · 2023: 18 · 2022: 6
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-04-28)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- University of Melbourne
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- N-acetylcysteine, mental illness, antioxidant activity, anti-inflammatory activity, glutamate modulation, negative symptoms of schizophrenia, autism spectrum disorder, depression, obsessive-compulsive disorder, substance use disorders, neurodevelopmental disorders, bipolar disorder, anxiety disorders, chronic pain, adjuvant therapy, clinical trial evidence
- MeSH terms
- Acetylcysteine, Anxiety Disorders, Bipolar Disorder, Humans, Obsessive-Compulsive Disorder, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.